| Journal | British journal of hospital medicine (London, England : 2005) |
| Study Type | Clinical Study |
| Population | Human participants |
This review addresses a critical gap in epilepsy care where one-third of patients experience drug-resistant seizures. Given that CBD is now FDA-approved for specific epilepsy syndromes, understanding the broader evidence base helps clinicians navigate treatment options for refractory cases.
This clinical review examines the anticonvulsant properties of cannabis phytocannabinoids, particularly CBD and THC, in treating epilepsy. The authors highlight that approximately 30% of epilepsy patients have medication-resistant seizures, creating a significant unmet medical need. While the evidence base has expanded over recent decades, the review notes persistent reluctance among clinicians and regulatory bodies regarding cannabis use in epilepsy. The authors emphasize the need for better education about cannabis therapeutics to improve patient access to these medicines.
“This review reinforces what we’ve seen clinically – CBD can be genuinely helpful for certain epilepsy patients, particularly those with treatment-resistant forms. The regulatory approval of Epidiolex has provided a clear pathway, though access and cost remain significant barriers for many families.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- How effective is medical cannabis for treating epilepsy?
- Which patients with epilepsy might benefit most from medical cannabis?
- What are the main active compounds in medical cannabis for epilepsy?
- Why are some clinicians hesitant to prescribe medical cannabis for epilepsy?
- Is medical cannabis safe for long-term epilepsy treatment?
FAQ
How effective is medical cannabis for treating epilepsy?
Research shows that specific phytocannabinoids, particularly cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), possess anticonvulsant properties and have demonstrated effectiveness in treating seizures. The clinical evidence base has been growing over recent decades, establishing both efficacy and safety profiles for cannabis-based epilepsy treatments.
Which patients with epilepsy might benefit most from medical cannabis?
Medical cannabis may be particularly beneficial for the approximately 30% of epilepsy patients who experience drug-resistant seizures that don’t respond to traditional antiseizure medications. Cannabis-based treatments appear effective across different age groups, including pediatric patients with treatment-resistant epilepsy.
What are the main active compounds in medical cannabis for epilepsy?
The two primary therapeutic compounds are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), both phytocannabinoids derived from the cannabis plant. These compounds have been specifically shown to have anticonvulsant properties that can help reduce seizure frequency and severity.
Why are some clinicians hesitant to prescribe medical cannabis for epilepsy?
Despite growing clinical evidence, many clinicians and medical regulatory bodies remain reluctant to recommend cannabis for epilepsy patients. This hesitancy appears to stem from the need for more comprehensive education about cannabis’s therapeutic properties and the existing clinical evidence base.
Is medical cannabis safe for long-term epilepsy treatment?
Current research has been establishing safety profiles for cannabis-based epilepsy treatments alongside efficacy data. However, patients should work closely with healthcare providers to monitor for potential side effects and drug interactions, particularly when used in conjunction with other antiseizure medications.